Trial Profile

A real-world study Anlotinib hydrochloride capsules combined with immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Catequentinib (Primary) ; Programmed cell death-1 ligand-1 inhibitors
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

24 Oct 2023 Updated results (n=147; From Aug 2021 to May 2023) assessing the real world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer, presented at the 48th European Society for Medical Oncology Congress.
21 Oct 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com